Why the study?
Reducing blood pressure below standard targets in people with hypertension and CKD may be beneficial but could increase adverse events, and the optimal target remains unknown.
Do lower blood pressure targets (≤130/80 mmHg) reduce mortality, cardiovascular events, or progression to end-stage renal disease compared to standard targets in adults with hypertension and chronic kidney disease?
Population
7348 adults with hypertension and CKD across 6 RCTs
Comparison
Lower blood pressure targets (130/80 mmHg or lower) vs standard targets (140 to 160/90 to 100 mmHg or lower)
Design
Systematic review and meta-analysis of open-label RCTs with blinded outcome assessment
Follow-up
Mean 3.6 years (range 1.0 to 8.0 years)
Authors
Loading...
Lower targets confer no benefit in hypertensive CKD; challenges intensive BP goals and supports standard targets in practice and trials.
Do lower blood pressure targets (≤130/80 mmHg) reduce mortality, cardiovascular events, or progression to end-stage renal disease compared to standard targets in adults with hypertension and chronic kidney disease?
In patients with hypertension and chronic kidney disease, targeting a lower blood pressure (≤130/80 mmHg) does not significantly reduce mortality, cardiovascular events, or progression to end-stage renal disease compared to standard targets.
Erviti et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: